News and features

A new study suggests that silencing CXCL12, a gene involved in tissue scarring and repair, could help reduce the formation of scar tissue that can caused by radiotherapy. Ultimately, the researchers hope this approach could improve treatment outcomes for breast cancer patients undergoing radiotherapy and reconstructive surgery.

A one-time immunotherapy treatment using a patient’s own immune cells has shown long-lasting benefit for people with advanced melanoma, a serious form of skin cancer, according to new five-year follow-up data from a pivotal clinical trial.

A powerful new drug for advanced breast cancer can be used to treat emerging tumours, months before they have a chance to grow, helping to keep patients well for longer and delaying the need for later-line therapies including chemotherapy. Results of a global study, funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Institut Curie, Paris, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on 1 June 2025.

A promising new therapy can help patients with aggressive advanced breast cancer live longer and delays the need for further chemotherapy, new research has shown. Final results of the INAVO120 study, led by an international team of researchers including scientists at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, have demonstrated the potential of the new therapy combination for targeting PIK3CA-mutated hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer – a common form of the disease.

An immunotherapy helps patients live years longer without their cancer getting worse or coming back, a major phase III trial has found.

A new AI test can pick out which men with high-risk prostate cancer that has not spread will require life-extending drug abiraterone.

Using an innovative scientific approach, scientists have obtained a wealth of new data on many of the proteins responsible for regulating the cell cycle – a sequence of molecular events that culminates in the production of two daughter cells.

The Institute of Cancer Research, London, has welcomed the approval of a new combination of two drugs for ovarian cancer by the US regulatory body the Food and Drug Administration (FDA).

Researchers at The Institute of Cancer Research, London, have uncovered a hidden weakness in some breast cancer tumours that could lead to smarter treatment decisions.

New research into how cancer develops has uncovered more detail about the importance of the centromere, a region of human DNA that has a critical role in effective cell division.

Adaptive chemotherapy – a personalised approach to giving chemotherapy – can prolong survival in lab models of ovarian cancer, according to new results published in the journal Cancer Research.

The Institute of Cancer Research has welcomed new plans to deliver around one million square feet of state-of-the-art research and laboratory space for life-sciences companies in Sutton, south London, where they will be located next door to our researchers.